Clinical Trial: A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations

U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06800196) titled 'A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations' on Jan. 20.

Brief Summary: This is a Phase1, open-label, dose escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of KNT-0916 in patients with unresectable or metastatic solid tumors harboring FGFR2 alterations who have failed prior systemic therapy. This study is divided into 2 parts, dose escalation part(part A), dose expansion part(partB).

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Solid Tumors with FGFR2 Alterations, Adu...